Identification of a Primary Target of Thalidomide Teratogenicity
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Thalidomide Teratogenicity Target: In the late 1950s and early 1960s, thalidomide was prescribed to pregnant women as a cure for morning sickness, but it was then found to have developmental defects, most obviously, stunted limbs in thousands of babies. Although its use was banned worldwide, thalidomide has since been found to be a valuable treatment for a range of cancers, inflammatory disorders, and leprosy. Several hypotheses have been proposed, but the mechanism of action of thalidomide is unknown. Using zebrafish and chicken as animal models, Ito et al. (p. 1345 ) show that the protein cereblon is a primary target of thalidomide. Thalidomide exerts teratogenic effects by binding to cereblon and inhibiting associated enzymatic activity important for limb development. Knowing the mechanism of action of thalidomide should encourage the search for thalidomide derivatives without teratogenic activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [77]
In the citing paper
“Cereblon (CRBN), a substrate receptor for the cullin–RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“FlagCRBN-W386E and FlagCRBN-W400E, and the double point mutant FlagCRBN-Y384A/W386A (FlagCRBN-YW/AA, which is defective in IMiD binding (Ito et al., 2010; Lopez-Girona et al., 2012)) failed to bind endogenous GS (Figure 6C).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“The catastrophe was not a failure of pharmacokinetic scaling. Rather, the rodent species used for the original toxicology programs were largely resistant to thalidomide teratogenicity, while rabbits and primates are sensitive.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
In the citing paper
“The case directly drove the development of ICH S5 reproductive toxicology guidelines mandating evaluation in two species, typically one rodent and one non-rodent, and underlies the broader principle that species panels for toxicodynamic endpoints must be selected on mechanistic grounds rather than convention [55,56].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Effective targeted gene ‘knockdown’ in zebrafish
Nasevicius, A., & Ekker, S. C. (2000) · Nature Genetics · doi:10.1038/79951 · Cited by 2,483
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Sonic hedgehog mediates the polarizing activity of the ZPA
Riddle, R. D., Johnson, R. L., Laufer, E., & Tabin, C. (1993) · Cell · doi:10.1016/0092-8674(93)90626-2 · Cited by 2,307
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Groisman, R., Polanowska, J., Kuraoka, I., Sawada, J.-I., Saijo, M., Drapkin, R., Kisselev, A. F., Tanaka, K., & Nakatani, Y. (2003) · Cell · doi:10.1016/s0092-8674(03)00316-7 · Cited by 744
Back to the Future with Ubiquitin
Pickart, C. M. (2004) · Cell · doi:10.1016/s0092-8674(03)01074-2 · Cited by 697
Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery
Angers, S., Li, T., Yi, X., MacCoss, M. J., Moon, R. T., & Zheng, N. (2006) · Nature · doi:10.1038/nature05175 · Cited by 674
Jin, J., Arias, E. E., Chen, J., Harper, J. W., & Walter, J. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.010 · Cited by 632
Cited by
Items 601–700 of 1,003
Chen, H., Chen, F., Pei, S., & Gou, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.03.035 · Cited by 45
Li, L., Xue, W., Shen, Z., Liu, J., Hu, M., Cheng, Z., Wang, Y., Chen, Y., Chang, H., Liu, Y., et al. (2020) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2020.06.013 · Cited by 40
Development of Photolenalidomide for Cellular Target Identification
Lin, Z., Amako, Y., Kabir, F., Flaxman, H. A., Budnik, B., & Woo, C. M. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c11920 · Cited by 45
Fischer, F., Grigolon, G., Benner, C., & Ristow, M. (2022) · Physiological Reviews · doi:10.1152/physrev.00017.2021 · Cited by 45
Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis
Ikura, H., Endo, J., Kitakata, H., Moriyama, H., Sano, M., & Fukuda, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116336 · Cited by 45
Recent advances in targeted protein degraders as potential therapeutic agents
Yang, N., Kong, B., Zhu, Z., Huang, F., Zhang, L., Lu, T., Chen, Y., Zhang, Y., & Jiang, Y. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10606-w · Cited by 45
Frank, C., Anthony, D. F., Vadrevu, S., Riddell, T., Day, J. P., McLeod, R., Adams, D. R., Baillie, G. S., & Houslay, M. D. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.06.003 · Cited by 45
Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia
Penna, F., Minero, V. G., Costamagna, D., Bonelli, G., Baccino, F. M., & Costelli, P. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.503773 · Cited by 41
Bertucci, C., & Tedesco, D. (2012) · Journal of Chromatography A · doi:10.1016/j.chroma.2012.09.046 · Cited by 45
Ubiquitylation of nuclear receptors: new linkages and therapeutic implications
Helzer, K. T., Hooper, C., Miyamoto, S., & Alarid, E. T. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0308 · Cited by 45
Drug target deconvolution by chemical proteomics
Raida, M. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.06.016 · Cited by 44
Pomalidomide: New immunomodulatory agent with potent antiproliferative effects
Richardson, P. G. G., Mark, T. M., & Lacy, M. Q. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.02.001 · Cited by 44
Revving the CAR – Combination strategies to enhance CAR T cell effectiveness
Bansal, R., & Reshef, R. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100695 · Cited by 44
What can we learn from the thalidomide experience: an ophthalmologic perspective
Miller, M. T., & Strömland, K. (2011) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e3283499f24 · Cited by 44
Drug Repurposing for the Treatment of Acute Myeloid Leukemia
Andresen, V., & Gjertsen, B. T. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00211 · Cited by 44
Shen, C., Nayak, A., Neitzel, L. R., Adams, A. A., Silver-Isenstadt, M., Sawyer, L. M., Benchabane, H., Wang, H., Bunnag, N., Li, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25634-z · Cited by 43
Small-Molecule Degraders beyond PROTACs—Challenges and Opportunities
Kastl, J. M., Davies, G., Godsman, E., & Holdgate, G. A. (2021) · SLAS Discovery · doi:10.1177/2472555221991104 · Cited by 43
Applications of protein ubiquitylation and deubiquitylation in drug discovery
Chen, Y., Xue, H., & Jin, J. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107264 · Cited by 43
Qiu, Y., Wei, X., Lam, J. W. Y., Qiu, Z., & Tang, B. Z. (2025) · ACS Nano · doi:10.1021/acsnano.4c14797 · Cited by 43
UCHL1is a biomarker of aggressive multiple myeloma required for disease progression
Hussain, S., Bedekovics, T., Chesi, M., Bergsagel, P. L., & Galardy, P. J. (2015) · Oncotarget · doi:10.18632/oncotarget.5727 · Cited by 43
From Anecdote to Targeted Therapy: The Curious Case of Thalidomide in Multiple Myeloma
Licht, J. D., Shortt, J., & Johnstone, R. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.019 · Cited by 37
Lenalidomide in the treatment of chronic lymphocytic leukemia
Itchaki, G., & Brown, J. R. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1313230 · Cited by 43
The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage
Wani, T. H., Chakrabarty, A., Shibata, N., Yamazaki, H., Guengerich, F. P., & Chowdhury, G. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.7b00127 · Cited by 43
Cereblon Maintains Synaptic and Cognitive Function by Regulating BK Channel
Choi, T.-Y., Lee, S., Kim, Y.-J., Bae, J. R., Lee, K. M., Jo, Y., Kim, S., Lee, A.-R., Choi, S., Choi, L., et al. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.2081-17.2018 · Cited by 43
Fibroblast Growth Factor 10 and Vertebrate Limb Development
Jin, L., Wu, J., Bellusci, S., & Zhang, J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2018.00705 · Cited by 43
Kunacheewa, C., & Orlowski, R. Z. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-112017-091045 · Cited by 43
Cassar, S. C., Beekhuijzen, M., Beyer, B. K., Chapin, R. E., Dorau, M., Hoberman, A. M., Krupp, E., Leconte, I., Stedman, D. B., Stethem, C. M., et al. (2019) · Reproductive Toxicology · doi:10.1016/j.reprotox.2019.02.004 · Cited by 43
Bellail, A. C., Jin, H. R., Lo, H.-Y., Jung, S. H., Hamdouchi, C., Kim, D., Higgins, R. K., Blanck, M., le Sage, C., Cross, B. C. S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh1486 · Cited by 42
Martinez-Høyer, S., Deng, Y., Parker, J., Jiang, J., Mo, A., Docking, T. R., Gharaee, N., Li, J., Umlandt, P., Fuller, M., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0497-9 · Cited by 42
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution
Xiao, Y., Yuan, Y., Liu, Y., Lin, Z., Zheng, G., Zhou, D., & Lv, D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00723 · Cited by 42
An Automated Electrochemical Flow Platform to Accelerate Library Synthesis and Reaction Optimization
Rial‐Rodríguez, E., Williams, J. D., Cantillo, D., Fuchß, T., Sommer, A., Eggenweiler, H., Kappe, C. O., & Laudadio, G. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202412045 · Cited by 42
SPLINTS: small-molecule protein ligand interface stabilizers
Fischer, E. S., Park, E., Eck, M. J., & Thomä, N. H. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.01.004 · Cited by 39
Chemical Protein Degradation Approach and its Application to Epigenetic Targets
Itoh, Y. (2018) · The Chemical Record · doi:10.1002/tcr.201800032 · Cited by 42
Crbn modulates calcium influx by regulating Orai1 during efferocytosis
Moon, H., Min, C., Kim, G., Kim, D., Kim, K., Lee, S.-A., Moon, B., Yang, S., Lee, J., Yang, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19272-0 · Cited by 42
The Ubiquitin System: An Emerging Therapeutic Target for Lung Cancer
Jin, J., Puranik, N., Bui, Q. T., Yadav, D., & Lee, P. C.-W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179629 · Cited by 42
CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma
Barankiewicz, J., Salomon‐Perzyński, A., Misiewicz-Krzemińska, I., & Lech‐Marańda, E. (2022) · Cancers · doi:10.3390/cancers14184492 · Cited by 42
Srivastava, R., Fernández-Ginés, R., Encinar, J. A., Cuadrado, A., & Wells, G. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.09.023 · Cited by 42
Thalidomide embryopathy: Follow‐up of cases born between 1959 and 2010
Kowalski, T. W., Sanseverino, M. T. V., Schüler‐Faccini, L., & Vianna, F. S. L. (2015) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.23376 · Cited by 42
Predictive in silico Off-Target Profiling in Drug Discovery
Schmidt, F., Matter, H., Heßler, G., & Czich, A. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.13.202 · Cited by 42
The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound
Shortt, J., Hsu, A., Martin, B. P., Doggett, K., Matthews, G. M., Doyle, M., Ellul, J., Jockel, T. E., Andrews, D. M., Hogg, S. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.008 · Cited by 42
Bird, S. A., & Pawlyn, C. (2023) · Blood · doi:10.1182/blood.2023019637 · Cited by 41
Li, F., Aljahdali, I. A. M., & Ling, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116206 · Cited by 36
Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy
Chen, S., Chen, Z., Lu, L., Zhao, Y., Zhou, R., Xie, Q., Shu, Y., Lin, J., Yu, X., & Wang, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115403 · Cited by 41
Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma
Lum, E. L., Huang, E., Bunnapradist, S., Pham, T. N., & Danovitch, G. M. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.11.024 · Cited by 41
Nishimura, N., Radwan, M. O., Amano, M., Endo, S., Fujii, E., Hayashi, H., Ueno, S., Ueno, N., Tatetsu, H., Hata, H., et al. (2019) · Cancer Science · doi:10.1111/cas.14154 · Cited by 41
Belair, D. G., Lu, G., Waller, L. E., Gustin, J. A., Collins, N. D., & Kolaja, K. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-59542-x · Cited by 41
Maneiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 41
Hu, M., Li, Y., Li, J., Zhou, H., Liu, C., Liu, Z., Gong, Y., Ying, B., & Xie, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114775 · Cited by 41
Krasavin, M., Adamchik, M., Bubyrev, A. I., Heim, C., Maiwald, S. A., Zhukovsky, D., Zhmurov, P. A., Bunev, A. S., & Hartmann, M. D. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114990 · Cited by 41
PROTAC: targeted drug strategy. Principles and limitations
Koroleva, O. A., Dutikova, Y. V., Trubnikov, A. V., Zenov, F. A., Manasova, E. V., Shtil, A. A., & Kurkin, A. V. (2022) · Russian Chemical Bulletin · doi:10.1007/s11172-022-3659-z · Cited by 41
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy
Li, X.-M., Zhao, Z., Xiao, Y., Xia, Q., Zhou, P., Wang, S., Wu, H., & Hu, J. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00394-2 · Cited by 41
Zhu, P., Stanisheuski, S., Franklin, R., Vogel, A., Vesely, C. H., Reardon, P. N., Sluchanko, N. N., Beckman, J. S., Karplus, P. A., Mehl, R. A., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00191 · Cited by 41
Salicylic Acid Induces Mitochondrial Injury by Inhibiting Ferrochelatase Heme Biosynthesis Activity
Gupta, V., Liu, S., Ando, H., Ishii, R., Tateno, S., Kaneko, Y., Yugami, M., Sakamoto, S., Yamaguchi, Y., Nureki, O., et al. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.087940 · Cited by 42
Self-citationTreatment advances and prognosis for patients with adult T-cell leukemia-lymphoma
Katsuya, H., & Ishitsuka, K. (2017) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.17008 · Cited by 41
Niedermolekulare PROTACs: neue Wege zum Abbau von Proteinen
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie · doi:10.1002/ange.201507978 · Cited by 40
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Ria, R., Melaccio, A., Racanelli, V., & Vacca, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061765 · Cited by 40
What influences the activity of Degrader−Antibody conjugates (DACs)
Guo, Y., Li, X., Xie, Y., & Wang, D. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116216 · Cited by 40
Redox mechanisms of environmental toxicants on male reproductive function
Hussain, T., Metwally, E., Murtaza, G., Kalhoro, D. H., Chughtai, M. I., Tan, B., Ömür, A. D., Tunio, S. A., Akbar, M., & Kalhoro, M. S. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1333845 · Cited by 40
Ronnebaum, S. M., Patterson, C., & Schisler, J. C. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1180 · Cited by 40
Target identification of bioactive compounds
Tashiro, E., & Imoto, M. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.10.081 · Cited by 40
Warkus, E. L. L., Yuen, A. A. Y. Q., Lau, C. G. Y., & Marikawa, Y. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv209 · Cited by 40
Transcriptional profiling of cytochrome P450 genes in the liver of adult zebrafish, Danio rerio
Kubota, A., Kawai, Y. K., Yamashita, N., Lee, J., Kondoh, D., Zhang, S., Nishi, Y., Suzuki, K., Kitazawa, T., & Teraoka, H. (2019) · The Journal of Toxicological Sciences · doi:10.2131/jts.44.347 · Cited by 40
Pierceall, W. E., Amatangelo, M. D., Bahlis, N. J., Siegel, D. S. D., Rahman, A. H., Oekelen, O. V., Neri, P. E., Young, M. H., Chung, W., Serbina, N. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1781 · Cited by 40
Shrestha, P., Davis, D. A., Jaeger, H. K., Stream, A., Aisabor, A. I., & Yarchoan, R. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009091 · Cited by 40
A comprehensive review of BET-targeting PROTACs for cancer therapy
Zhou, X., Zhao, F., Xu, Y.-T., Guan, Y., Yu, T., Zhang, Y., Duan, Y., & Zhao, Y. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117033 · Cited by 40
Neri, P. E., Barwick, B. G., Jung, D., Patton, J. C., Maity, R., Tagoug, I., Stein, C. K., Tilmont, R., Leblay, N., Ahn, S., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0061 · Cited by 40
Physiological Functions of the Ubiquitin Ligases Nedd4-1 and Nedd4-2
Rotin, D., & Prag, G. (2023) · Physiology · doi:10.1152/physiol.00023.2023 · Cited by 39
London, N. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00570 · Cited by 39
Thalidomide for tocilizumab‐resistant ascites with TAFRO syndrome
Tatekawa, S., Umemura, K., Fukuyama, R., Kohno, A., Taniwaki, M., Kuroda, J., & Morishita, Y. (2015) · Clinical Case Reports · doi:10.1002/ccr3.284 · Cited by 39
A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma
Arora, M., Gowda, S., & Tuscano, J. M. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716652861 · Cited by 39
Bavley, C. C., Rice, R. C., Fischer, D. K., Fakira, A. K., Byrne, M., Kosovsky, M., Rizzo, B. K., Prete, D. D., Alaedini, A., Morón, J. A., et al. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.0599-17.2018 · Cited by 39
Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera
Kim, K., Lee, D. H., Park, S., Jo, S.-H., Ku, B., Park, S. G., Park, B. C., Jeon, Y. U., Ahn, S., Kang, C. H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56177-5 · Cited by 36
Zhang, Y., Wang, L., Xu, M., Zhao, T., Kuang, L., & Hua, D. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901778 · Cited by 39
The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
Paradžik, T., Bandini, C., Mereu, E., Labrador, M., Taìana, E., Amodio, N., Neri, A., & Piva, R. (2021) · Cancers · doi:10.3390/cancers13061235 · Cited by 39
Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives
Li, J., Cai, Z., Li, X., & Zhuang, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01223 · Cited by 39
Understanding the multiple biological aspects leading to myeloma
Boyle, E. M., Davies, F. E., Leleu, X. P., & Morgan, G. J. (2014) · Haematologica · doi:10.3324/haematol.2013.097907 · Cited by 39
Cryo-electron microscopy-based drug design
Cebi, E., Lee, J., Subramani, V. K., Bak, N., Oh, C., & Kim, K. K. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1342179 · Cited by 38
Therapeutic Target Identification and Drug Discovery Driven by Chemical Proteomics
Zou, M., Zhou, H., Gu, L., Zhang, J., & Fang, L. (2024) · Biology · doi:10.3390/biology13080555 · Cited by 38
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
Rajkumar, S. V. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.354.3798330 · Cited by 38
Physicochemistry of Cereblon Modulating Drugs Determines Pharmacokinetics and Disposition
Kong, N. R., Liu, H., Che, J., & Jones, L. H. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00475 · Cited by 38
Designing HDAC-PROTACs: Lessons Learned So Far
Fischer, F., Avelar, L. A. A., Murray, L., & Kurz, T. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0206 · Cited by 38
PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
Liu, X., Wang, A., Shi, Y., Dai, M., Liu, M., & Cai, H. (2023) · Molecules · doi:10.3390/molecules28031217 · Cited by 38
Oliveira, N. A. S., Pinho, B. R., & Oliveira, J. M. A. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105138 · Cited by 38
Nevins, S., McLoughlin, C. D., Oliveros, A., Stein, J. B., Rashid, M. A., Hou, Y., Jang, M., & Lee, K. (2023) · Small · doi:10.1002/smll.202300744 · Cited by 38
A biotin targeting chimera (BioTAC) system to map small molecule interactomes in situ
Tao, A. J., Jiang, J., Gadbois, G. E., Goyal, P., Boyle, B. T., Mumby, E. J., Myers, S. A., English, J. G., & Ferguson, F. M. (2023) · Nature Communications · doi:10.1038/s41467-023-43507-5 · Cited by 38
Chowdhury, G., Shibata, N., Yamazaki, H., & Guengerich, F. P. (2013) · Chemical Research in Toxicology · doi:10.1021/tx4004215 · Cited by 38
Lenalidomide for the treatment of relapsed and refractory multiple myeloma
Gorgun, G., Donk, V. D., Groen, Jakubikova, Mitsiades, C., Hideshima, T., Richardson, P., Nijhof, Raymakers, Lokhorst, H., et al. (2012) · Cancer Management and Research · doi:10.2147/cmar.s27087 · Cited by 38
The impact of thalidomide use in birth defects in Brazil
Vianna, F. S. L., Kowalski, T. W., Fraga, L. R., Sanseverino, M. T. V., & Schüler‐Faccini, L. (2016) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2016.09.015 · Cited by 38
Prediction of developmental chemical toxicity based on gene networks of human embryonic stem cells
Yamane, J., Aburatani, S., Imanishi, S., Akanuma, H., Nagano, R., Kato, T., Sone, H., Ohsako, S., & Fujibuchi, W. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw450 · Cited by 37
“For example, thalidomide [3-(N-phthalimido) glutarimide], a well-known versatile drug used to treat such serious diseases as red nodules in Hansen’s disease, multiple myeloma and HIV, was responsible for various forms of birth defects when it was administered to pregnant women, via mechanisms that remain unknown to th…”
BackgroundA novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer
Lier, S., Sellmer, A., Orben, F., Heinzlmeir, S., Krauß, L., Schneeweis, C., Hassan, Z., Schneider, C., Patricia Gloria Schäfer, A., Pongratz, H., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105505 · Cited by 37
Sakamoto, S., Hatakeyama, M., Ito, T., & Handa, H. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.022 · Cited by 37
Self-citationZhao, S., Guan, G., Liu, J., Liu, A., Li, Y., Yin, H., & Luo, J. (2017) · Parasites & Vectors · doi:10.1186/s13071-017-2421-0 · Cited by 37
Schiedel, M., Moroglu, M., Ascough, D. M. H., Chamberlain, A. E. R., Kamps, J. J. A. G., Sekirnik, A. R., & Conway, S. J. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201812164 · Cited by 37
Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma
Ikeda, S., & Tagawa, H. (2021) · Cancer Science · doi:10.1111/cas.15087 · Cited by 37
SJPYT-195: A Designed Nuclear Receptor Degrader That Functions as a Molecular Glue Degrader of GSPT1
Huber, A. D., Li, Y., Lin, W., Galbraith, A. N., Mishra, A., Porter, S. N., Wu, J., Gee, R. R. F., Zhuang, W., Pruett‐Miller, S. M., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00223 · Cited by 37
Key Considerations in Targeted Protein Degradation Drug Discovery and Development
Qin, L., Dai, H., & Wang, J. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.934337 · Cited by 37
Grifagni, D., Lenci, E., Santis, A. D., Orsetti, A., Barracchia, C. G., Tedesco, F., Puglielli, R. B., Lucarelli, F., Lauriola, A., Assfalg, M., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00498 · Cited by 37
Genetic susceptibility to teratogens: State of the art
Cassina, M., Salviati, L., Gianantonio, E. D., & Clementi, M. (2012) · Reproductive Toxicology · doi:10.1016/j.reprotox.2012.05.004 · Cited by 37
Teratogenicity: a mechanism based short review on common teratogenic agents
Jamkhande, P. G., Chintawar, K. D., & Chandak, P. G. (2014) · Asian Pacific Journal of Tropical Disease · doi:10.1016/s2222-1808(14)60600-9 · Cited by 37
Tateno, S., Iida, M., Fujii, S., Suwa, T., Katayama, M., Tokuyama, H., Yamamoto, J., Ito, T., Sakamoto, S., Handa, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61027-w · Cited by 36
Self-citation
Metadata
- Authors
- Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H.
- Affiliations
- Tokyo Institute of Technology (JP)
- Tohoku University (JP)
- Astellas Pharma (Japan) (JP)
- Corresponding author
- Ito, Takumi
- Ando, Hideki
- Handa, Hiroshi
- Venue
- Science
- Published
- 2010-03-12
- Volume
- 327
- Issue
- 5971
- Pages
- 1345-1350
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1997952190
- Cited by
- 2,136
- References
- 36
- Citations by year
- 2026: 141 · 2025: 189 · 2024: 189 · 2023: 174 · 2022: 179 · 2021: 169 · 2020: 171 · 2019: 120 · 2018: 126 · 2017: 104 · 2016: 100 · 2015: 114 · 2014: 99 · 2013: 103 · 2012: 67
- FWCI
- 74.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Developmental Biology › Congenital limb and hand anomalies
- Keywords
- thalidomide, teratogenicity, cereblon, E3 ubiquitin ligase, DDB1, CUL4A, limb malformations, FGF8, limb outgrowth, ubiquitination, zebrafish, chick embryo, drug repurposing
- MeSH terms
- Animals, Carrier Proteins, Chick Embryo, DNA-Binding Proteins, Embryo, Nonmammalian, Fibroblast Growth Factors, Forelimb, HeLa Cells, Humans, Peptide Hydrolases, Teratogens, Thalidomide, Zebrafish, Gene Expression Regulation, Developmental, Zebrafish Proteins, Ubiquitin-Protein Ligases, Cullin Proteins, Embryonic Development, Adaptor Proteins, Signal Transducing, Mutant Proteins, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.